He received afatinib as frontline treatment and showed a partial response; however, the right lung lesion progressed after 14 months of treatment...Because EGFR testing using resected tissue showed only the original mutation, we switched his regimen to pemetrexed and carboplatin...Although an association between MET amplification and rapidly progressive lung cancer has been predicted previously, to the best of our knowledge, this is the first report on the potential contribution of other mutations, such as those in RNA-binding motif 10, during MET-driven rapid progression. Our report highlights the importance of more active utilization of molecular profiling for the emergence of resistance during tyrosine kinase inhibitor use and the early identification of MET amplification and timely initiation of MET-targeted therapy, such as MET inhibitors in combination with EGFR-TKIs, to potentially mitigate rapid disease progression and clinical deterioration.

Six cycles of adjuvant paclitaxel liposome (240 mg) plus carboplatin (650 mg) were administered, and the patient remains clinically well with no evidence of disease to date. This case supports early recognition and timely management of suspicious MCTs in young adults.

P2, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Based on the above results, the patient received chemotherapy with carboplatin and pemetrexed disodium combined with targeted therapy using the EGFR tyrosine kinase inhibitor (TKI) almonertinib mesylate tablets. The two cases reported in this paper demonstrate that targeted and immune treatment plans based on the tissue of origin of the tumor can serve as a clinical option for patients with CUP. These findings may provide new information and references for clinical decision-making in the management of CUP.

There is a pressing need to explore and support initiatives for effective implementation of guidelines and identifying the causes of nonadherence.

P3, N=0, Withdrawn, Relmada Therapeutics, Inc. | N=302 --> 0 | Not yet recruiting --> Withdrawn

P3, N=0, Withdrawn, Relmada Therapeutics, Inc. | N=85 --> 0 | Not yet recruiting --> Withdrawn

Here, we demonstrated that SOX4 not only induces resistance to cisplatin but also to oxaliplatin and carboplatin, suggesting its potential role as a multidrug resistance gene. Given that cisplatin preferentially targets highly proliferating cells, SOX4-driven metabolic deceleration enables cervical cancer cells to evade cisplatin-mediated cytotoxicity. Together, these findings demonstrate that SOX4 enhances cisplatin resistance in cervical cancer through SIRT1-upregulated suppression of glycolysis.

They sensitized ALDH+ CSC-like cells to carboplatin, while paclitaxel response remained unchanged. EVs were found to be enriched in hsa-miR-100-5p, hsa-miR-122-5p, and hsa-let-7i-5p based on miRNA array analysis, and these findings were further validated by qRT-PCR. These findings reveal the dual roles of BM-MSC-EVs: enhancing carboplatin sensitivity while promoting tumor progression and angiogenesis.

Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin-pemetrexed for this molecularly defined population.

Given unresectability, the patient received toripalimab (240 mg) combined with docetaxel and cisplatin every 3 weeks. To our knowledge, this is the first reported case of toripalimab-based chemoimmunotherapy demonstrating an early partial response and short-term disease control in unresectable maxillary sinus NUT carcinoma. It supports the potential role of PD-1 blockade integrated with platinum-taxane chemotherapy as a component of multimodal management for sinonasal NUT carcinomas.

His treatment was started with docetaxel, receiving five cycles with good tolerance, after which he received hormonal treatment. After the infusion of 11 mL, the patient presented pharyngeal obstruction with dyspnoea, facial erythema, genital pruritus, and cervical pain that required treatment with intramuscular epinephrine. The results of the allergy study were not concordant with clinical presentation and confirmed the poor predictive value of taxane skin tests.